Charles Schwab Investment Management Inc Aclaris Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 261,298 shares of ACRS stock, worth $525,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
261,298
Previous 33,079
689.92%
Holding current value
$525,208
Previous $50,000
642.0%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding ACRS
# of Institutions
100Shares Held
88.3MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN14.3MShares$28.6 Million15.31% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$19.4 Million0.02% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$17.9 Million2.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.66MShares$13.4 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.77MShares$9.59 Million0.46% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $134M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...